Safinamide Spherical Agglomerates Flowability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Safinamide or its pharmaceutically acceptable salts, typically in needle-shape crystals form, exhibit low flowability and handling difficulties, necessitating additional grinding steps for formulation into oral tablets, which complicates downstream processing and affects drug stability and performance.
Innovation Solution
A process involving the preparation of spherical agglomerates of safinamide or its salt by suspending it in a hydrocarbon solvent and adding a bridging liquid to promote aggregation, resulting in enhanced flowability and easier handling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If needle-shape crystals of safinamide are used directly, then the active ingredient can be obtained through standard isolation procedures, but the flowability is poor and handling is difficult
Solution Approach 1:
The invention applies spheroidality by transforming needle-shaped crystals into spherical agglomerates through a fluidized bed process. The spherical shape fundamentally improves flowability and handling characteristics while maintaining the active ingredient's therapeutic properties. This geometric transformation directly resolves the contradiction between ease of manufacture and ease of operation.
Solution Approach 2:
The invention changes physical parameters of the safinamide particles by subjecting them to fluidized bed processing with controlled temperature, gas flow, and residence time. These parameter changes transform the original needle-shaped crystals into spherical agglomerates with improved flowability, thereby resolving the contradiction between maintaining manufacturing simplicity and improving operational ease.
2Ease of operation
If additional grinding steps are introduced to improve flowability, then handling becomes easier, but the process complexity increases and drug stability may be affected
Solution Approach 1:
The invention performs the shape transformation action preliminarily during the isolation step itself, rather than requiring subsequent grinding operations. By integrating the spherical agglomeration into the isolation process through fluidized bed treatment, the handling difficulties are resolved before the material enters downstream processing, thereby reducing overall process complexity while improving ease of operation.
Solution Approach 2:
The invention replaces mechanical grinding systems with a fluidized bed system that uses gas flow and fluid dynamics to achieve spherical agglomeration. This substitution eliminates the need for additional grinding equipment and operations, reducing device complexity while simultaneously improving handling characteristics through spherical particle morphology.
3Ease of manufacture
If needle-shape crystals are processed further, then formulation can proceed, but micrometric properties are altered and may affect in vivo performance
Solution Approach 1:
The invention creates spherical copies or replicas of the original needle-shaped crystals through controlled agglomeration in a fluidized bed. The resulting spherical agglomerates replicate the therapeutic properties of the original crystals while adopting a spherical morphology that improves flowability and formulation readiness without compromising crystalline form stability or in vivo performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The spherical agglomerates exhibit improved flowability and ease of handling, reducing the need for micronization and physical stress, while maintaining the active ingredient's polymorphic and crystalline form, facilitating efficient pharmaceutical composition preparation.
Implementation Method 1
adding a bridging liquid to the resulting suspension until aggregation is observed
Data Source
AI summary
The present invention relates to a process for the preparation of spherical agglomerates of safinamide or a pharmaceutically acceptable salt thereof, to the agglomerates thus obtained and to a process for preparing a pharmaceutical composition including said agglomerates.